Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: Lessons from clinical data and BMT models

Naoko Kato, Jiro Kitaura, Noriko Doki, Yukiko Komeno, Naoko Watanabe-Okochi, Katsuhiro Togami, Fumio Nakahara, Toshihiko Oki, Yutaka Enomoto, Yumi Fukuchi, Hideaki Nakajima, Yuka Harada, Hironori Harada, Toshio Kitamura

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Two types of mutations of a transcription factor CCAAT-enhancer binding protein α (C/EBPα) are found in leukemic cells of 5%-14% of acute myeloid leukemia (AML) patients: N-terminal mutations expressing dominant negative p30 and C-terminal mutations in the basic leucine zipper domain. Our results showed that a mutation of C/EBPα in one allele was observed in AML after myelodysplastic syndrome, while the 2 alleles are mutated in de novo AML. Unlike an N-terminal frame-shift mutant (C/EBPα-Nm)-transduced cells, a C-terminal mutant (C/EBPα-Cm)-transduced cells alone induced AML with leukopenia in mice 4-12 months after bone marrow transplantation. Coexpression of both mutants induced AML with marked leukocytosis with shorter latencies. Interestingly, C/EBPα-Cm collaborated with an Flt3-activating mutant Flt3-ITD in inducing AML. Moreover, C/EBPα-Cm strongly blocked myeloid differentiation of 32Dcl3 cells, suggesting its class II mutation-like role in leukemogenesis. Although C/EBPα-Cm failed to inhibit transcriptional activity of wild-type C/EBPα, it suppressed the synergistic effect between C/EBPα and PU.1. On the other hand, C/EBPα-Nm inhibited C/EBPα activation in the absence of PU.1, despite low expression levels of p30 protein generated by C/EBPα-Nm. Thus, 2 types of C/EBPα mutations are implicated in leukemogenesis, involving different and cooperating molecular mechanisms.

Original languageEnglish
Pages (from-to)221-233
Number of pages13
JournalBlood
Volume117
Issue number1
DOIs
Publication statusPublished - 2011 Jan 6

Fingerprint

CCAAT-Enhancer-Binding Proteins
Mutation
Acute Myeloid Leukemia
Alleles
Leucine Zippers
Myelodysplastic Syndromes
Leukocytosis
Leukopenia
Bone Marrow Transplantation
Cell Differentiation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kato, N., Kitaura, J., Doki, N., Komeno, Y., Watanabe-Okochi, N., Togami, K., ... Kitamura, T. (2011). Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: Lessons from clinical data and BMT models. Blood, 117(1), 221-233. https://doi.org/10.1182/blood-2010-02-270181

Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis : Lessons from clinical data and BMT models. / Kato, Naoko; Kitaura, Jiro; Doki, Noriko; Komeno, Yukiko; Watanabe-Okochi, Naoko; Togami, Katsuhiro; Nakahara, Fumio; Oki, Toshihiko; Enomoto, Yutaka; Fukuchi, Yumi; Nakajima, Hideaki; Harada, Yuka; Harada, Hironori; Kitamura, Toshio.

In: Blood, Vol. 117, No. 1, 06.01.2011, p. 221-233.

Research output: Contribution to journalArticle

Kato, N, Kitaura, J, Doki, N, Komeno, Y, Watanabe-Okochi, N, Togami, K, Nakahara, F, Oki, T, Enomoto, Y, Fukuchi, Y, Nakajima, H, Harada, Y, Harada, H & Kitamura, T 2011, 'Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: Lessons from clinical data and BMT models', Blood, vol. 117, no. 1, pp. 221-233. https://doi.org/10.1182/blood-2010-02-270181
Kato, Naoko ; Kitaura, Jiro ; Doki, Noriko ; Komeno, Yukiko ; Watanabe-Okochi, Naoko ; Togami, Katsuhiro ; Nakahara, Fumio ; Oki, Toshihiko ; Enomoto, Yutaka ; Fukuchi, Yumi ; Nakajima, Hideaki ; Harada, Yuka ; Harada, Hironori ; Kitamura, Toshio. / Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis : Lessons from clinical data and BMT models. In: Blood. 2011 ; Vol. 117, No. 1. pp. 221-233.
@article{6276286ec9884073b9278398bc55ddf5,
title = "Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: Lessons from clinical data and BMT models",
abstract = "Two types of mutations of a transcription factor CCAAT-enhancer binding protein α (C/EBPα) are found in leukemic cells of 5{\%}-14{\%} of acute myeloid leukemia (AML) patients: N-terminal mutations expressing dominant negative p30 and C-terminal mutations in the basic leucine zipper domain. Our results showed that a mutation of C/EBPα in one allele was observed in AML after myelodysplastic syndrome, while the 2 alleles are mutated in de novo AML. Unlike an N-terminal frame-shift mutant (C/EBPα-Nm)-transduced cells, a C-terminal mutant (C/EBPα-Cm)-transduced cells alone induced AML with leukopenia in mice 4-12 months after bone marrow transplantation. Coexpression of both mutants induced AML with marked leukocytosis with shorter latencies. Interestingly, C/EBPα-Cm collaborated with an Flt3-activating mutant Flt3-ITD in inducing AML. Moreover, C/EBPα-Cm strongly blocked myeloid differentiation of 32Dcl3 cells, suggesting its class II mutation-like role in leukemogenesis. Although C/EBPα-Cm failed to inhibit transcriptional activity of wild-type C/EBPα, it suppressed the synergistic effect between C/EBPα and PU.1. On the other hand, C/EBPα-Nm inhibited C/EBPα activation in the absence of PU.1, despite low expression levels of p30 protein generated by C/EBPα-Nm. Thus, 2 types of C/EBPα mutations are implicated in leukemogenesis, involving different and cooperating molecular mechanisms.",
author = "Naoko Kato and Jiro Kitaura and Noriko Doki and Yukiko Komeno and Naoko Watanabe-Okochi and Katsuhiro Togami and Fumio Nakahara and Toshihiko Oki and Yutaka Enomoto and Yumi Fukuchi and Hideaki Nakajima and Yuka Harada and Hironori Harada and Toshio Kitamura",
year = "2011",
month = "1",
day = "6",
doi = "10.1182/blood-2010-02-270181",
language = "English",
volume = "117",
pages = "221--233",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis

T2 - Lessons from clinical data and BMT models

AU - Kato, Naoko

AU - Kitaura, Jiro

AU - Doki, Noriko

AU - Komeno, Yukiko

AU - Watanabe-Okochi, Naoko

AU - Togami, Katsuhiro

AU - Nakahara, Fumio

AU - Oki, Toshihiko

AU - Enomoto, Yutaka

AU - Fukuchi, Yumi

AU - Nakajima, Hideaki

AU - Harada, Yuka

AU - Harada, Hironori

AU - Kitamura, Toshio

PY - 2011/1/6

Y1 - 2011/1/6

N2 - Two types of mutations of a transcription factor CCAAT-enhancer binding protein α (C/EBPα) are found in leukemic cells of 5%-14% of acute myeloid leukemia (AML) patients: N-terminal mutations expressing dominant negative p30 and C-terminal mutations in the basic leucine zipper domain. Our results showed that a mutation of C/EBPα in one allele was observed in AML after myelodysplastic syndrome, while the 2 alleles are mutated in de novo AML. Unlike an N-terminal frame-shift mutant (C/EBPα-Nm)-transduced cells, a C-terminal mutant (C/EBPα-Cm)-transduced cells alone induced AML with leukopenia in mice 4-12 months after bone marrow transplantation. Coexpression of both mutants induced AML with marked leukocytosis with shorter latencies. Interestingly, C/EBPα-Cm collaborated with an Flt3-activating mutant Flt3-ITD in inducing AML. Moreover, C/EBPα-Cm strongly blocked myeloid differentiation of 32Dcl3 cells, suggesting its class II mutation-like role in leukemogenesis. Although C/EBPα-Cm failed to inhibit transcriptional activity of wild-type C/EBPα, it suppressed the synergistic effect between C/EBPα and PU.1. On the other hand, C/EBPα-Nm inhibited C/EBPα activation in the absence of PU.1, despite low expression levels of p30 protein generated by C/EBPα-Nm. Thus, 2 types of C/EBPα mutations are implicated in leukemogenesis, involving different and cooperating molecular mechanisms.

AB - Two types of mutations of a transcription factor CCAAT-enhancer binding protein α (C/EBPα) are found in leukemic cells of 5%-14% of acute myeloid leukemia (AML) patients: N-terminal mutations expressing dominant negative p30 and C-terminal mutations in the basic leucine zipper domain. Our results showed that a mutation of C/EBPα in one allele was observed in AML after myelodysplastic syndrome, while the 2 alleles are mutated in de novo AML. Unlike an N-terminal frame-shift mutant (C/EBPα-Nm)-transduced cells, a C-terminal mutant (C/EBPα-Cm)-transduced cells alone induced AML with leukopenia in mice 4-12 months after bone marrow transplantation. Coexpression of both mutants induced AML with marked leukocytosis with shorter latencies. Interestingly, C/EBPα-Cm collaborated with an Flt3-activating mutant Flt3-ITD in inducing AML. Moreover, C/EBPα-Cm strongly blocked myeloid differentiation of 32Dcl3 cells, suggesting its class II mutation-like role in leukemogenesis. Although C/EBPα-Cm failed to inhibit transcriptional activity of wild-type C/EBPα, it suppressed the synergistic effect between C/EBPα and PU.1. On the other hand, C/EBPα-Nm inhibited C/EBPα activation in the absence of PU.1, despite low expression levels of p30 protein generated by C/EBPα-Nm. Thus, 2 types of C/EBPα mutations are implicated in leukemogenesis, involving different and cooperating molecular mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=78650975508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650975508&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-02-270181

DO - 10.1182/blood-2010-02-270181

M3 - Article

C2 - 20884804

AN - SCOPUS:78650975508

VL - 117

SP - 221

EP - 233

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -